| CARLAT PUBLISHING

The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 1 CME credit. Read More

Most of us are pretty familiar with Alcoholics Anonymous (AA), and asking about AA attendance and participation is routine during appointments with patients trying to curb their alcohol use. But what about Narcotics Anonymous (NA)? Read More

Using Medical Management in Treating Opioid Use Disorder

To set the stage for understanding medical management, we need to go back about 20 years to the inception of the landmark COMBINE Study. This study was a very large clinical trial for alcohol use disorder (AUD) that compared naltrexone, acamprosate, and their combination, and also looked at two behavioral interventions. Read More

Opioid Treatment Options

Opioid use disorder (OUD) treatment can be tricky, in part because it doesn’t respond well to detox and counseling-only approaches. The overwhelming majority of people relapse after such attempts, or even become more vulnerable to overdose because of decreased tolerance after detoxing. Read More

FDA Approves Lucemyra—But Is It Better Than Clonidine?

On May 16, 2018, the FDA announced its approval of Lucemyra (lofexidine) as a drug to help patients withdraw from opioids. Like clonidine, lofexidine is an alpha-2 agonist, but it is touted as causing less orthostatic hypotension and therefore being somewhat safer to use. Read More

Psychiatry Practice Boosters, Second Edition (2018)
Teaches you the key points of 42 of the most clinically relevant studies in psychiatry published...
READ MORE

General Psychiatry
Using SAMe In Clinical Practice with Garrett Rossi, MD
Read More

Addiction Treatment
Supervised Drug Consumption Sites
Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.
Listen now